Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS
· Delayed Price · Currency is USD
24.59
+0.24 (0.99%)
Aug 14, 2025, 10:44 AM EDT
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 474.60B JPY in the quarter ending June 30, 2025, with 8.81% growth. This brings the company's revenue in the last twelve months to 1.92T, up 14.09% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,924.68B JPY
Revenue Growth
+14.09%
P/S Ratio
3.36
Revenue / Employee
97.38M JPY
Employees
19,765
Market Cap
44.89B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.17M |
| BioStem Technologies | 332.45M |
Daiichi Sankyo Company News
- 13 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO - CNBC
- 14 days ago - Daiichi Sankyo reports Q1 results - Seeking Alpha
- 4 weeks ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 4 weeks ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 7 weeks ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 7 weeks ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 2 months ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC